Abstract
Mifepristone (Roussel Uclaf, Paris, France) is an antiprogestin which binds to the progesterone receptor, thereby preventing progesterone from expressing its biological effect. Mifepristone, in combination with a prostaglandin analogue, is used for termination of early pregnancy in several countries, including Sweden [3, 17]. The use of antiprogestins for contraceptive purposes is currently being evaluated and recent results indicate that this may very well be possible.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Loriaux DL, Merriam GR (1994) The antiprogesterone RU 486 delays the midcycle gonadotrophin surge and ovulation in gonadotrophin-releasing hormone induced cycles. Fertil Steril 62: 28–34
Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Merriam GR, Loriaux DL (1992) Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab 74: 565–570
Bygdeman M, Swahn ML (1985) Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 32: 45–51
Gemzell Danielsson K, Hamberg M (1994) The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (Naproxen) on uterine fluid PGF2a concentrations. Hum Reprod 9: 1626–1630
Gemzell Danielsson K, Svalander P, Swahn ML, Johannisson E, Bygdeman M (1994) Effect of a single postovulatory dose of RU 486 on the endometrial maturation in the implantation phase. Hum Reprod 9: 2398–2404
Gemzell Danielsson K, Swahn ML, Bygdeman M (1997) The effect of various doses of mifepristone on leukaemia inhibitory factor expression in the midluteal phase–an immunohistoctemical study. Hum Reprod 12: 1293–1297
Gemzell Danielsson K, Swahn ML, Svalander P, Bygdeman M (1993) Early luteal phase treatment with RU 486 for fertility regulation. Hum Reprod 8: 870–873
Gemzell Danielsson K, Westlund P, Johannisson E, Swahn ML, Seppais M, Bygdeman M (1997) Effect of low weekly doses of mifepristone on ovarian function and endometrial development. Hum Reprod 12: 124–131
Glasier AF, Thong Kj, Dewar M, Mackie M, Baird DT (1992) Mifepristone (RU 486) compared with high-dose estrogen and progesterone emergency postcoital contraception. N Engl J Med 327: 1041–1044
Kekkonen R, Croxatto HB, Lähteenmäki P, Salvatierra AM, Tuominen J (1995) Effects of intermittent antiprogestin RU 486 combined with cyclic medroxyprogesterone acetate on folliculogenesis and ovulation. Hum Reprod 10: 287–292
Li TC, Dockery P, Thomas P, Rogers AW, Lenton EA, Cooke ID (1988) The effects of progesterone blockade in the luteal phase of normal fertile women. Fertil Steril 50: 732–742
Liu JH, Garzo G, Monis Strenkel C, Ulmann A, Yen SCC (1987) Disruption of follicular maturation and delay of ovulation after administration of the antiprogestin RU 486. J Clin Endocrinol Metab 65: 1135–1140
Marions L, Gemzell Danielsson K, Bygdeman M (1998) The effect of antiprogestin in integrin expression in human endometrium. An immunohistochemical study. Hum Reprod 4: 491–495
Mäentausta 0, Svalander P, Gemzell Danielsson K, Bygdeman M, Vikho R (1993) The effects of an antiprogesterone, mifepristone, and an antiestrogen, tamoxifen, on endometrial 17b-hydroxysteroid dehydrogenase and progestin and estrogen receptors during the luteal phase of the menstrual cycle. An immunohistochemical study. J Endocrinol Metab 77: 913–918
Swahn ML, Bygdeman M, Xing S, Cekan S, Masironi B, Johannisson E (1990) The effect of RU 486 administered during the early luteal phase on bleeding pattern, hormonal parameters and endometrium. Hum Reprod 5: 402–408
Swahn ML, Johannisson E, Daniore V, de la Torre B, Bygdeman M (1988) The effect of RU 486 administered during the proliferative and secretory phase of the cycle on the bleeding pattern, hormonal parameters and the endometrium. Hum Reprod 3: 915–921
Ulmann A, Silvestre L, Chemama L, Rezvani Y, Renault M, Aquillaume CJ, Baulieu EE (1992) Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Acta Obstet Gynecol Scand 71: 278–283
WHO task force on methods for the determination of the fertile period (1983) A prospective multicentre trial of the ovulation method of natural family planning. III. Characterization of the menstrual cycle and the fertile phase. Fertil Steril 40: 773–778
Webb AMC, Russel J, Elstein M (1992) Comparison of Yuzpe regimen, danazol and mifepristone (RU 486) in oral postcoital contraception. Br Med J 305: 927–931
Marions L, Gemzell Danielsson K, Swahn ML, Bygdeman M (1998) Contraceptive efficacy of low doses of mifepristone. Fertil Steril (in press)
Wilcox AJ, Weinberg CR, Baird DT (1995) Timing of sexual intercourse in relation to ovulation. N Engl J Med 333: 1517–1521
Rights and permissions
Copyright information
© 1999 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bygdeman, M., Danielsson, K.G., Marions, L., Swahn, ML. (1999). Antiprogestins — A New Challenge for Female Contraception. In: Fertility Control — Update and Trends. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86696-8_11
Download citation
DOI: https://doi.org/10.1007/978-3-642-86696-8_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-86698-2
Online ISBN: 978-3-642-86696-8
eBook Packages: Springer Book Archive